{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:41:29Z","timestamp":1791823289864,"version":"4.3.4"},"reference-count":36,"publisher":"American Diabetes Association","issue":"5","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,5,1]]},"abstract":"<jats:p>A growing body of evidence implicates ceramide and\/or its glycosphingolipid metabolites in the pathogenesis of insulin resistance. We have developed a highly specific small molecule inhibitor of glucosylceramide synthase, an enzyme that catalyzes a necessary step in the conversion of ceramide to glycosphingolipids. In cultured 3T3-L1 adipocytes, the iminosugar derivative N-(5\u2032-adamantane-1\u2032-yl-methoxy)-pentyl-1-deoxynojirimycin (AMP-DNM) counteracted tumor necrosis factor-\u03b1\u2013induced abnormalities in glycosphingolipid concentrations and concomitantly reversed abnormalities in insulin signal transduction. When administered to mice and rats, AMP-DNM significantly reduced glycosphingolipid but not ceramide concentrations in various tissues. Treatment of ob\/ob mice with AMP-DNM normalized their elevated tissue glucosylceramide levels, markedly lowered circulating glucose levels, improved oral glucose tolerance, reduced A1C, and improved insulin sensitivity in muscle and liver. Similarly beneficial metabolic effects were seen in high fat\u2013fed mice and ZDF rats. These findings provide further evidence that glycosphingolipid metabolites of ceramide may be involved in mediating the link between obesity and insulin resistance and that interference with glycosphingolipid biosynthesis might present a novel approach to the therapy of states of impaired insulin action such as type 2 diabetes.<\/jats:p>","DOI":"10.2337\/db06-1619","type":"journal-article","created":{"date-parts":[[2007,4,30]],"date-time":"2007-04-30T12:48:34Z","timestamp":1177937314000},"page":"1341-1349","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":264,"title":["Pharmacological Inhibition of Glucosylceramide Synthase Enhances Insulin Sensitivity"],"prefix":"10.2337","volume":"56","author":[{"given":"Johannes M.","family":"Aerts","sequence":"first","affiliation":[{"name":"Department of Medical Biochemistry, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roelof","family":"Ottenhoff","sequence":"additional","affiliation":[{"name":"Macrozyme, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Powlson","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, University of Cambridge, Cambridge, U.K"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Grefhorst","sequence":"additional","affiliation":[{"name":"Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"van Eijk","sequence":"additional","affiliation":[{"name":"Macrozyme, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Dubbelhuis","sequence":"additional","affiliation":[{"name":"Macrozyme, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Aten","sequence":"additional","affiliation":[{"name":"Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folkert","family":"Kuipers","sequence":"additional","affiliation":[{"name":"Centre for Liver, Digestive, and Metabolic Disease, Academic Hospital Groningen, University of Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille J.","family":"Serlie","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Wennekes","sequence":"additional","affiliation":[{"name":"Gorlaeus Laboratories, Leiden Institute of Chemistry, Leiden University, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaswinder K.","family":"Sethi","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, University of Cambridge, Cambridge, U.K"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"O'Rahilly","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, University of Cambridge, Cambridge, U.K"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermen S.","family":"Overkleeft","sequence":"additional","affiliation":[{"name":"Gorlaeus Laboratories, Leiden Institute of Chemistry, Leiden University, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031210513123500_R1","doi-asserted-by":"crossref","unstructured":"Unger RH: Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology\u2008144:5159\u20135165,2003","DOI":"10.1210\/en.2003-0870"},{"key":"2022031210513123500_R2","doi-asserted-by":"crossref","unstructured":"Savage DB, Petersen KF, Shulman GI: Mechanisms of insulin resistance in humans and possible links with inflammation. Hypertension\u200845:828\u2013833,2005","DOI":"10.1161\/01.HYP.0000163475.04421.e4"},{"key":"2022031210513123500_R3","doi-asserted-by":"crossref","unstructured":"Hegarty BD, Furler SM, Ye J, Cooney GJ, Kraegen EW: The role of intramuscular lipid in insulin resistance. Acta Physiol Scand\u2008178:373\u2013383,2003","DOI":"10.1046\/j.1365-201X.2003.01162.x"},{"key":"2022031210513123500_R4","doi-asserted-by":"crossref","unstructured":"Adams JM 2nd, Pratipanawatr T, Berria R, Wang E, DeFronzo RA, Sullards MC, Mandarino LJ: Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes\u200853:25\u201331,2004","DOI":"10.2337\/diabetes.53.1.25"},{"key":"2022031210513123500_R5","doi-asserted-by":"crossref","unstructured":"Summers SA: Ceramides in insulin resistance and lipotoxicity. Prog\u2008Lipid Res\u200845:42\u201372,2006","DOI":"10.1016\/j.plipres.2005.11.002"},{"key":"2022031210513123500_R6","doi-asserted-by":"crossref","unstructured":"Kolter T, Proia RL, Sandhoff K: Combinatorial ganglioside biosynthesis. J Biol Chem\u2008277:25859\u201325862,2002","DOI":"10.1074\/jbc.R200001200"},{"key":"2022031210513123500_R7","doi-asserted-by":"crossref","unstructured":"Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes, J Clin Invest\u2008115:1111\u20131119,2005","DOI":"10.1172\/JCI25102"},{"key":"2022031210513123500_R8","doi-asserted-by":"crossref","unstructured":"Peraldi P, Spiegelman B: TNF-alpha and insulin resistance: summary and future prospects. Mol Cell Biochem\u2008182:169\u2013175,1998","DOI":"10.1007\/978-1-4615-5647-3_18"},{"key":"2022031210513123500_R9","doi-asserted-by":"crossref","unstructured":"Miura A, Miura A, Kajita K, Ishizawa M, Kanoh Y, Kawai Y, Natsume Y, Sakuma H, Yamamoto Y, Yasuda K, Ishizuka T: Inhibitory effect of ceramide on insulin-induced protein kinase Czeta translocation in rat adipocytes. Metabolism\u200852:19\u201324,2003","DOI":"10.1053\/meta.2003.50011"},{"key":"2022031210513123500_R10","doi-asserted-by":"crossref","unstructured":"Stratford S, Hoehn KL, Liu F, Summers SA: Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt\/protein kinase B. J Biol Chem\u2008279:26608\u201336615,2004","DOI":"10.1074\/jbc.M406499200"},{"key":"2022031210513123500_R11","doi-asserted-by":"crossref","unstructured":"Powell DJ, Turban S, Gray A, Hajduch E, Hundal HS: Intracellular ceramide synthesis and PKCzeta activation play an essential role in palmitate-induced insulin resistance in rat L6 skeletal muscle cells. Biochem J\u2008382:619\u2013629,2004","DOI":"10.1042\/BJ20040139"},{"key":"2022031210513123500_R12","doi-asserted-by":"crossref","unstructured":"Ruvolo PP: Intracellular signal transduction pathways activated by ceramide and its metabolites. Pharmacol Res\u200847:383\u2013392,2003","DOI":"10.1016\/S1043-6618(03)00050-1"},{"key":"2022031210513123500_R13","doi-asserted-by":"crossref","unstructured":"Allende ML, Proia RL: Lubricating cell signalling pathways with gangliosides. Curr Opin Struct Biol\u200812:587\u2013592,2002","DOI":"10.1016\/S0959-440X(02)00376-7"},{"key":"2022031210513123500_R14","doi-asserted-by":"crossref","unstructured":"Rebbaa A, Hurh J, Yamamoto H, Kersey DS, Bremer EG: Ganglioside GM3 inhibition of EGF receptor mediated signal transduction. Glycobiology\u20086:399\u2013406,1996","DOI":"10.1093\/glycob\/6.4.399"},{"key":"2022031210513123500_R15","doi-asserted-by":"crossref","unstructured":"Tagami S, Tagami S, Inokuchi Ji J, Kabayama K, Yoshimura H, Kitamura F, Uemura S, Ogawa C, Ishii A, Saito M, Ohtsuka Y, Sakaue S, Igarashi Y: Ganglioside GM3 participates in the pathological conditions of insulin resistance. J Biol\u2008Chem\u2008277:3085\u20133092,2002","DOI":"10.1074\/jbc.M103705200"},{"key":"2022031210513123500_R16","doi-asserted-by":"crossref","unstructured":"Yamashita T, Yamashita T, Hashiramoto A, Haluzik M, Mizukami H, Beck S, Norton A, Kono M, Tsuji S, Daniotti JL, Werth N, Sandhoff R, Sandhoff K, Proia RL.: Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc Natl Acad Sci U S A\u2008100:3445\u20133449,2003","DOI":"10.1073\/pnas.0635898100"},{"key":"2022031210513123500_R17","doi-asserted-by":"crossref","unstructured":"Kabayama K, Kabayama K, Sato T, Kitamura F, Uemura S, Kang BW, Igarashi Y, Inokuchi J: TNF alpha-induced insulin resistance in adipocytes as a membrane microdomain disorder: involvement of ganglioside GM3. Glycobiology\u200815:21\u201329,2004","DOI":"10.1093\/glycob\/cwh135"},{"key":"2022031210513123500_R18","doi-asserted-by":"crossref","unstructured":"Shayman JA, Abe A, Hiraoka M: A turn in the road: how studies on the pharmacology of glucosylceramide synthase inhibitors led to the identification of a lysosomal phospholipase A2 with ceramide transacylase activity. Glycoconj J\u200820:25\u201332,2004","DOI":"10.1023\/B:GLYC.0000016739.32089.55"},{"key":"2022031210513123500_R19","doi-asserted-by":"crossref","unstructured":"Aerts JM, Hollak C, Boot R, Groener A: Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention. Philos Trans R Soc Lond B Biol Sci\u2008358:905\u2013914,2003","DOI":"10.1098\/rstb.2003.1273"},{"key":"2022031210513123500_R20","doi-asserted-by":"crossref","unstructured":"Nugent C, Prins JB, Whitehead JP, Savage D, Wentworth JM, Chatterjee VK, O'Rahilly S: Potentiation of glucose uptake in 3T3\u2013L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation. Mol Endocrinol\u200815:1729\u20131738,2001","DOI":"10.1210\/me.15.10.1729"},{"key":"2022031210513123500_R21","doi-asserted-by":"crossref","unstructured":"Overkleeft HS, Renkema GH, Neele J, Vianello P, Hung IO, Strijland A, van der Burg AM, Koomen GJ, Pandit UK, Aerts JM: Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase. J Biol Chem\u2008273:26522\u201326527,1998","DOI":"10.1074\/jbc.273.41.26522"},{"key":"2022031210513123500_R22","doi-asserted-by":"crossref","unstructured":"Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem\u2008226:497\u2013509,1957","DOI":"10.1016\/S0021-9258(18)64849-5"},{"key":"2022031210513123500_R23","doi-asserted-by":"crossref","unstructured":"Taketomi T, Hara A, Uemura K, Sugiyama E: Rapid method of preparation of lysoglycosphingolipids and their confirmation by delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry. J Biochem (Tokyo)\u2008120:573\u2013579,1996","DOI":"10.1093\/oxfordjournals.jbchem.a021452"},{"key":"2022031210513123500_R24","doi-asserted-by":"crossref","unstructured":"Neville DC, Coquard V, Priestman DA, te Vruchte DJ, Sillence DJ, Dwek RA, Platt FM, Butters TD: Analysis of fluorescently labeled glycosphingolipid-derived oligosaccharides following ceramide glycanase digestion and anthranilic acid labeling. Anal Biochem\u2008331:275\u2013282,2004","DOI":"10.1016\/j.ab.2004.03.051"},{"key":"2022031210513123500_R25","doi-asserted-by":"crossref","unstructured":"Van Weely S, Van Leeuwen MB, Jansen ID, De Bruijn MA, Brouwer-Kelder EM, Schram AW, Sa Miranda MC, Barranger JA, Petersen EM, Goldblatt J, Stotz H, Schwarzmann G, Sandhoff K, Svennerholm L, Erikson A, Tager JM, Aerts JM: Clinical phenotype of Gaucher disease in relation to properties of mutant glucocerebrosidase in cultured fibroblasts. Biochim Biophys Acta\u20081096:301\u2013311,1991","DOI":"10.1016\/0925-4439(91)90066-I"},{"key":"2022031210513123500_R26","doi-asserted-by":"crossref","unstructured":"Andersson U, Butters TD, Dwek RA, Platt FM: N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol\u200859:821\u2013829,2000","DOI":"10.1016\/S0006-2952(99)00384-6"},{"key":"2022031210513123500_R27","doi-asserted-by":"crossref","unstructured":"Andersson U, Reinkensmeier G, Butters TD, Dwek RA, Platt FM: Inhibition of glycogen breakdown by iminosugars in vitro and in vivo. Biochem Pharmacol\u200867:697\u2013705,2004","DOI":"10.1016\/j.bcp.2003.09.036"},{"key":"2022031210513123500_R28","doi-asserted-by":"crossref","unstructured":"Ebina Y, Edery M, Ellis L, Standring D, Beaudoin J, Roth R, Rutter WJ: Expression of a functional human insulin receptor from a cloned cDNA in Chinese hamster ovary cells. Proc Natl Acad Sci U S A\u200882:8014\u20138018,1985","DOI":"10.1073\/pnas.82.23.8014"},{"key":"2022031210513123500_R29","doi-asserted-by":"crossref","unstructured":"van Dijk TH, Boer TS, Havinga R, Stellaard F, Kuipers F, Reijngoud DJ: Quantification of hepatic carbohydrate metabolism in conscious mice using serial blood and urine spots. Anal Biochem\u2008322:1\u201313,2003","DOI":"10.1016\/j.ab.2003.07.008"},{"key":"2022031210513123500_R30","doi-asserted-by":"crossref","unstructured":"Grefhorst A, van Dijk TH, Hammer A, van der Sluijs FH, Havinga R, Havekes LM, Romijn JA, Groot PH, Reijngoud DJ, Kuipers F: Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob\/ob mice. Am J Physiol Endocrinol Metab\u2008289:E829\u2013E838,2005","DOI":"10.1152\/ajpendo.00165.2005"},{"key":"2022031210513123500_R31","doi-asserted-by":"crossref","unstructured":"Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, Platt F, Butters T, Dwek R, Moyses C, Gow I, Elstein D, Zimran A: Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT918) to decrease substrate biosynthesis. Lancet\u2008355:1481\u20131485,2000","DOI":"10.1016\/S0140-6736(00)02161-9"},{"key":"2022031210513123500_R32","doi-asserted-by":"crossref","unstructured":"Yildiz Y, Matern H, Thompson B, Allegood JC, Warren RL, Ramirez DM, Hammer RE, Hamra FK, Matern S, Russell DW: Mutation of beta-glucosidase 2 causes glycolipid storage disease and impaired male fertility. J Clin Invest\u2008116:2985\u20132994,2006","DOI":"10.1172\/JCI29224"},{"key":"2022031210513123500_R33","doi-asserted-by":"crossref","unstructured":"Boot RG, Verhoek M, Donker-Koopman W, Strijland A, van Marle J, Overkleeft HS, Wennekes T, Aerts JM: Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2. J Biol Chem\u2008282:1305\u20131312,2006","DOI":"10.1074\/jbc.M610544200"},{"key":"2022031210513123500_R34","doi-asserted-by":"crossref","unstructured":"Scott LJ, Spencer CM: Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs\u200859:521\u2013549,2000","DOI":"10.2165\/00003495-200059030-00012"},{"key":"2022031210513123500_R35","doi-asserted-by":"crossref","unstructured":"Fleet GW, Fellows LE, Winchester B: Plagiarizing plants: amino sugars as a class of glycosidase inhibitors. Ciba Found Symp\u2008154:112\u2013122,1990","DOI":"10.1002\/9780470514009.ch9"},{"key":"2022031210513123500_R36","doi-asserted-by":"crossref","unstructured":"Nojima H, Kimura I, Chen FJ, Sugihara Y, Haruno M, Kato A, Asano N: Antihyperglycemic effects of N-containing sugars from Xanthocercis zambesiaca, Morus bombycis, Aglaonema treubii, and Castanospermum australe in streptozotocin-diabetic mice. J Nat Prod\u200861:397\u2013400,1998","DOI":"10.1021\/np970277l"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/56\/5\/1341\/388283\/zdb00507001341.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/56\/5\/1341\/388283\/zdb00507001341.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T12:10:10Z","timestamp":1667391010000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/56\/5\/1341\/15247\/Pharmacological-Inhibition-of-Glucosylceramide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,1]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db06-1619","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,1]]}}}